Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214

total

1,338.943

impact factor

6.257

average impact factor

Group Leader: Rafael Parra López

team

zoom

download

The group has maintained its commitment to the promotion of research achieving a remarkable success on competitive calls such as “RETOS”, where four different projects in collaboration with a number of Catalan research institutions have been funded. All these projects mobilize up to 1.9M€ in four years.

It has been of special relevance the finalization of 3 clinical trials, based on Advanced Therapies Medicinal Products, sponsored by Banc de Sang i Teixits and carried on the Hospital Vall d’Hebron Campus.

The reorganization of the “cellular” laboratory has optimized its support to research and during 2019 a new impulse will be given to the laboratory core of genomics. In addition we have integrated the biobank within the research structure. All three core facilities are offered to the VHIR community.

Globally, the scientific production has shown a positive evolution with 30 publications (44% 1st Quartile) and an IF: 111. Two young investigators have again achieved the doctoral degree.

19

total

84^.129

impact factor

4^.428

average impact factor

SELECTED ARTICLES

Borràs N, Batlle J, Pérez-Rodríguez A, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Cid AR, Bonanad S, Cabrera N, Moret A, Parra R, Mingot-Castellano ME, Balda I, Altisent C, Pérez-Montes R, Fisac RM, Iruín G, Herrero S, Soto I, de Rueda B, Jiménez-Yuste V, Alonso N, Vilariño D, Arija O, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Sarmiento L, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, César JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Cornudella R, Aguilar C, Vidal F, Corrales I.
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.
HAEMATOLOGICA 2017 Dec;102(12):2005-2014.
doi: 10.3324/haematol.2017.168765
IF: 9.090
Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Castro Quismondo N, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F, Corrales I.
Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.
HAEMATOLOGICA 2018 Oct 25.
doi: 10.3324/haematol.2018.203166
IF: 9.090
Closa L, Vidal F, Herrero MJ, Caro JL.
Design and Validation of a Multiplex KIR and HLA Class I Genotyping Method Using Next Generation Sequencing.
FRONT IMMUNOL 2018 Dec 19;9:2991.
doi: 10.3389/fimmu.2018.02991
IF: 5,511
Enrich E, Vidal F, Sánchez-Gordo F, Gómez-Zumaquero JM, Balas A, Rudilla F, Barea L, Castro A, Larrea L, Perez-Vaquero MA, Prat I, Querol S, Garrido G, Matesanz R, Carreras E, Duarte RF.
Analysis of the Spanish CCR5-?32 inventory of cord blood units: lower cell counts in homozygous donors.
BONE MARROW TRANSPLANT 2018 Jun;53(6):741-748.
doi: 10.1038/s41409-018-0114-8
IF: 4.497
Mirabel C, Puente-Massaguer E, del Mazo-Barbara A, Reyes B, Morton P, Gòdia F, Vives J.
Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.
JOURNAL OF TRANSLATIONAL MEDICINE 2018 Oct 24;16(1):291.
doi: 10.1186/s12967-018-1659-4.
IF: 4.197

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Rafael Parra López

Research Areas